Dmitry Balyasny’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Dmitry Balyasny’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-225,000	Closed	-$9.54M	–	3236
2023 Q4	$9.54M	Buy	+225,000	New	+$6.47M	0.02%	884

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Dmitry Balyasny's CERE Position: Q3 2024 in Review

Dmitry Balyasny sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 596,407 shares — an estimated $24.4M sold.

Dmitry Balyasny first reported a position in CERE in Q1 2023 and held it in 6 quarters. The position peaked at $82.3M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Dmitry Balyasny reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Dmitry Balyasny sold 596,407 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $24.4M.
Dmitry Balyasny first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Dmitry Balyasny's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $82.3M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.